For TNBC, the first-level NAT regimen is recommended in the Chinese breast cancer treatment guidelines, which include: (i) taxane, anthracycline, and cyclophosphamide; (ii) taxes anthracycline; (iii) taxane platinum. Here, BRD2 is linked to breast cancer.